Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Company to launch product after the expiry of semaglutide patent in India
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Subscribe To Our Newsletter & Stay Updated